Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis

NCT03520517 is registered in ClinicalTrials.gov with Biohaven Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03520517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03520517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of BHV-0223 in Subjects With Amyotrophic Lateral Sclerosis
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
February 2, 2018
Completion date
October 8, 2018
Enrollment
22 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

als, amyotrophic lateral sclerosis, lou gehrig disease, lou gehrig's disease, lou-gehrigs disease, motor neuron disease, amyotrophic lateral sclerosis